Allogeneic HLA-A*02-restricted WT1-specific T cells from mismatched donors are highly reactive but show off-target promiscuity
- PMID: 21821799
- DOI: 10.4049/jimmunol.1100852
Allogeneic HLA-A*02-restricted WT1-specific T cells from mismatched donors are highly reactive but show off-target promiscuity
Abstract
T cells recognizing tumor-associated Ags such as Wilms tumor protein (WT1) are thought to exert potent antitumor reactivity. However, no consistent high-avidity T cell responses have been demonstrated in vaccination studies with WT1 as target in cancer immunotherapy. The aim of this study was to investigate the possible role of negative thymic selection on the avidity and specificity of T cells directed against self-antigens. T cell clones directed against the HLA-A*0201-binding WT1(126-134) peptide were generated from both HLA-A*02-positive (self-HLA-restricted) and HLA-A*02-negative [nonself (allogeneic) HLA [allo-HLA]-restricted] individuals by direct ex vivo isolation using tetramers or after in vitro priming and selection. The functional avidity and specificity of these T cell clones was analyzed in-depth. Self-HLA-restricted WT1-specific clones only recognized WT1(126-134) with low avidities. In contrast, allo-HLA-restricted WT1 clones exhibited profound functional reactivity against a multitude of HLA-A*02-positive targets, even in the absence of exogenously loaded WT1 peptide, indicative of Ag-binding promiscuity. To characterize this potential promiscuity, reactivity of the T cell clones against 400 randomly selected HLA-A*0201-binding peptides was investigated. The self-HLA-restricted WT1-specific T cell clones only recognized the WT1 peptide. In contrast, the allo-HLA-restricted WT1-reactive clones recognized besides WT1 various other HLA-A*0201-binding peptides. In conclusion, allogeneic HLA-A*02-restricted WT1-specific T cells isolated from mismatched donors may be more tumor-reactive than their autologous counterparts but can show specific off-target promiscuity of potential clinical importance. As a result of this, administration of WT1-specific T cells generated from HLA-mismatched donors should be performed with appropriate precautions against potential off-target effects.
Similar articles
-
In vitro methods for generating CD8+ T-cell clones for immunotherapy from the naïve repertoire.J Immunol Methods. 2006 Mar 20;310(1-2):40-52. doi: 10.1016/j.jim.2005.11.023. Epub 2006 Jan 26. J Immunol Methods. 2006. PMID: 16469329
-
T-cell responses directed against multiple HLA-A*0201-restricted epitopes derived from Wilms' tumor 1 protein in patients with leukemia and healthy donors: identification, quantification, and characterization.Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8799-807. doi: 10.1158/1078-0432.CCR-05-1314. Clin Cancer Res. 2005. PMID: 16361568
-
Use of B cell-bound HLA-A2 class I monomers to generate high-avidity, allo-restricted CTLs against the leukemia-associated protein Wilms tumor antigen.Blood. 2004 Jun 15;103(12):4613-5. doi: 10.1182/blood-2003-11-3903. Epub 2004 Feb 26. Blood. 2004. PMID: 14988155
-
WT1 as a novel target antigen for cancer immunotherapy.Curr Cancer Drug Targets. 2002 Mar;2(1):45-54. doi: 10.2174/1568009023334088. Curr Cancer Drug Targets. 2002. PMID: 12188920 Review.
-
Immunotherapy for leukemia targeting the Wilms' tumor gene.Leuk Lymphoma. 2001 Jul;42(3):267-73. doi: 10.3109/10428190109064583. Leuk Lymphoma. 2001. PMID: 11699391 Review.
Cited by
-
High CTLA-4 expression on Th17 cells results in increased sensitivity to CTLA-4 coinhibition and resistance to belatacept.Am J Transplant. 2014 Mar;14(3):607-14. doi: 10.1111/ajt.12600. Am J Transplant. 2014. PMID: 24730049 Free PMC article.
-
Role of T cell receptor affinity in the efficacy and specificity of adoptive T cell therapies.Front Immunol. 2013 Aug 21;4:244. doi: 10.3389/fimmu.2013.00244. eCollection 2013. Front Immunol. 2013. PMID: 23970885 Free PMC article.
-
Generation of CD20-specific TCRs for TCR gene therapy of CD20low B-cell malignancies insusceptible to CD20-targeting antibodies.Oncotarget. 2016 Nov 22;7(47):77021-77037. doi: 10.18632/oncotarget.12778. Oncotarget. 2016. PMID: 27776339 Free PMC article.
-
RHAMM/HMMR (CD168) is not an ideal target antigen for immunotherapy of acute myeloid leukemia.Haematologica. 2012 Oct;97(10):1539-47. doi: 10.3324/haematol.2012.065581. Epub 2012 Apr 24. Haematologica. 2012. PMID: 22532518 Free PMC article.
-
Enhanced-affinity murine T-cell receptors for tumor/self-antigens can be safe in gene therapy despite surpassing the threshold for thymic selection.Blood. 2013 Jul 18;122(3):348-56. doi: 10.1182/blood-2013-01-478164. Epub 2013 May 14. Blood. 2013. PMID: 23673862 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials